Benitec Biopharma Inc.

Stage 4 · Declining · week 3

As of Oct 22, 2026, Benitec Biopharma is in Stage 4, the downtrend phase, now in week 3 (since Oct 6, 2026). It closed at $8.82, 46.6% below its 52-week high and below its 200-day average, which is falling.

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. More about the company

$8.82

+3.76% today

$308M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is BNTC early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 30w

S2 39w

S4 17w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 9w → S1 12w → S4 7w → S1 1w → S2 30w → S3 1w → S2 39w → S3 6w → S4 4w → S1 1w → S2 9w → S3 4w → S4 17w → S1 6w → S4 2w → S1 7w → S2 5w → S3 2w → S4 2w current

Total tracked: 165 weeks across 19 stage runs.

BNTC among Biotechnology335th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…335	BNTCBenitec Biopharma Inc.	Stage 4 · wk 3	26	−10.3%

vs 52W High

-46.6%

$8.11 lo$16.52 hi

46.6% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 3

1w13w26w

Week 3, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-24.2%

200 DMA: $11.64 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.77x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-10.3%

-23.1%

-30.6%

YTD

-29.9%

-44.4%

Scan Membership

Breakout Watch

Latest: 2024-10-14

6 appearances in last 60 days. First seen: 2020-06-19.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 3 · Vol 0.77x

2026-10-21S4

Wk 3 · Vol 0.81x

2026-10-20S4

Wk 3 · Vol 1.86x

2026-10-19S4

Wk 2 · Vol 1.05x

2026-10-16S4

Wk 2 · Vol 0.87x

2026-10-15S4

Wk 2 · Vol 0.85x

2026-10-14S4

Wk 2 · Vol 0.91x

2026-10-13S4

Wk 2 · Vol 0.85x

2026-10-12S4

Wk 1 · Vol 1.14x

2026-10-09S4

Wk 1 · Vol 0.41x

2026-10-08S4

Wk 1 · Vol 1.36x

2026-10-07S4

Wk 1 · Vol 1.12x

Moving averages & range

50 DMA

$10.89

200 DMA

$11.64

52W High

$16.52

52W Low

$8.11

5D Low

$8.11

Resistance levels (recent highs)

20d High

$10.02

60d High

$13.78

120d High

$13.78

250d High

$16.52

Next resistance

+13.6%

to 20d High

ROE

-33.2%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 1.7

Benitec Biopharma: quick answers

What stage is Benitec Biopharma in?

As of Oct 22, 2026, Benitec Biopharma (BNTC) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 6, 2026 and is in week 3. What the four stages mean

Is Benitec Biopharma in an uptrend?

No. Benitec Biopharma is in a Stage 4 downtrend. It trades 24.2% below its 200-day average, which is falling.

How far is Benitec Biopharma from its 52-week high?

Benitec Biopharma closed at $8.82 on Oct 22, 2026, 46.6% below its 52-week high of $16.52. Its 52-week low is $8.11.

How has Benitec Biopharma performed over the past year?

As of Oct 22, 2026, Benitec Biopharma is down 44.4% over the past year and down 29.9% so far in 2026.

Which sector and industry is Benitec Biopharma in?

Benitec Biopharma is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene, which is in phase 1b/2a for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.